Reliant aims for $95m from public listing
This article was originally published in Clinica
Executive Summary
Laser systems developer Reliant Technologies announced on August 16 that it is targeting funding of $95m from an initial public offering. The company will offer around 30 million shares at a price of $3.83 per share, in a bid to fund development of its Fraxel family of laser devices used for treating various skin conditions and surgical scars.